TCA
RMD icon

Transcend Capital Advisors’s ResMed RMD Stock Holding History

Transcend Capital Advisors’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-908
Closed -$204K – 848
2026
Q1 		$204K Buy
+908
New +$226K 0.02% 681
2025
Q2 		– Sell
-1,405
Closed -$315K – 700
2025
Q1 		$315K Sell
1,405
-61
-4% -$14.2K 0.02% 466
2024
Q4 		$335K Buy
+1,466
New +$353K 0.02% 418

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Transcend Capital Advisors's RMD Position: Q2 2026 in Review

Transcend Capital Advisors sold out of ResMed (RMD) in Q2 2026, closing a stake of 908 shares — an estimated $204K sold.

Transcend Capital Advisors first reported a position in RMD in Q4 2024 and held it in 3 quarters. The position peaked at $335K in Q4 2024. 887 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Transcend Capital Advisors reported no remaining ResMed position as of Q2 2026 after selling out during the quarter.
  • Transcend Capital Advisors sold 908 ResMed shares in Q2 2026, an estimated $204K.
  • Transcend Capital Advisors first reported a position in ResMed in Q4 2024 and held it in 3 quarters.
  • Transcend Capital Advisors's ResMed position peaked at $335K in Q4 2024.
  • 887 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.